LinkedIn

Distributors / Reps

Find out how IMDA can help you achieve excellence in specialty sales and marketing.


  

 

Meet an IMDA Member - OE Meyer Co

OE Meyer
www.oemeyer.com


Contact
Kevin Turner
Vice president sales and marketing
kturner@oemeyer.com
(419) 625-3054


OE Meyer is an anesthesia/respiratory specialty dealer focused on helping our customers navigate the complex healthcare landscape and address product fulfillment needs and services. Doing what's right has resulted in long-standing customer relationships and satisfaction.

In today's environment of healthcare supplier consolidation, it can be frustrating when suppliers seem more focused on internal interests than on you. OE Meyer Co. is a diverse team of problem solvers that deliver continuity of service, expertise, and consistent representation. We'll be there when you need convenient, cost-effective, and comprehensive solutions. 

Here's what you can expect from OE Meyer Co.:

  • Professionally trained employee owners.
  • Same day shipping for orders placed by 3:00 p.m. EST.
  • 99 percent of established product orders ship same day.
  • Customer-based shipping preferences. Dedicated OE Meyer Co. drivers can deliver to many customer locations, or within 1-2 days via common carrier.
  • Product samples: Just ask. We can help.
  • No-hassle return policy.

            www.oemeyer.com

IMDA eNews       11/14/2017


 

 Who says the big guys can't play in the innovation game? Given how much money big medical device companies spend each year on acquisitions, it's clear that they have a desire for innovation. And yet, they hold back on R&D spending because large corporations tend to need predictability, repeatability and scalability. But that doesn't have to be the case, said Steve Geist, a director of R&D at Edwards Lifesciences, speaking at MD&M Minneapolis recently. Here are five reasons why: Big guys have 1) an R&D infrastructure in place; they just have to fix it so it becomes less of an exercise in documentation and more of a basis for actual engineering; 2) tools and capabilities that small companies don't; 3) the talent to innovate, though they have to unleash it; 4) the right contacts among clinicians and key opinion leaders; and 5) deeper pockets than small companies.

Health technology hazards identified. Ransomware and other cybersecurity threats were deemed the No. 1 health technology hazard by ECRI Institute, as it launched its Top 10 Health Technology Hazards list for 2018. Multiple ransomware and other malware variants have infected healthcare organizations, as well as other private and public organizations, throughout the world, according to the company. Endoscope reprocessing remains in the No. 2 spot this year, as healthcare facilities continue to struggle with consistently and effectively cleaning, disinfecting, and sterilizing instruments between uses.
Health systems: Customers or suppliers?
Where are the next-generation medical technologies coming from? Could be from one of your customer's "Innovation Centers." Last week, Partners HealthCare System in Boston announced the closing of $171.1 million in capital to invest in early-stage life sciences companies. That same week, Texas Medical Center launched a $25 million venture fund to support early-stage companies developing healthcare technologies. And in September, the Cedars-Sinai accelerator kicked off its third class of healthcare startups. Companies receive an investment of $120,000; mentorship from Cedars-Sinai physicians, researchers, healthcare professionals and executives; and dedicated office space in the Cedars-Sinai Innovation Space, adjacent to the medical center in Los Angeles.
CDI @ TMC. Johnson & Johnson Medical Devices Companies opened the Center for Device Innovation at the Texas Medical Center (CDI @ TMC), a collaboration with Johnson & Johnson Innovation LLC and Texas Medical Center to accelerate development -from concept to commercialization-of medical devices technologies. J&J says the 26,000-square-foot facility is appointed with all the tools its staff may need to translate ideas to products, including a machine shop, a mechanical testing lab, an electronics workspace and component lab, a 3D printing lab and a virtual reality demonstration area.
Parenteral solutions shortage must be addressed.
The American Hospital Association urged the Food and Drug Administration to take action to address the shortages of small-volume parenteral solutions, such as 50 and 100 milliliter injection bags of sodium chloride 0.9 percent, dextrose 5 percent, and IV nutritional products. "The AHA understands and appreciates that FDA has been working with Baxter and other major manufacturers of these products to address the current shortages," said AHA Executive Vice President Thomas Nickels, in a Nov. 7 letter to FDA Commissioner Scott Gottlieb, M.D. "We also appreciate your efforts to obtain alternative sources of the products, including from overseas suppliers. However, we strongly urge FDA to do more by pushing current manufacturers to not only continue to produce these products at their maximum capacity, but also to make investments to ensure an increasing supply for the future."